Skip to content

Author

G. Kollmorgen

We have 4 of 243 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Abstract INTRODUCTION Mounting evidence suggests overlapping pathology across Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD), yet its extent and clinical implications remain unclear. METHODS Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40, phosphorylated tau 181 (p‐tau181), neu...

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations
Open access Sep 2026

Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease

In CSF-confirmed participants, age emerged as the most consistent predictor of plasma biomarker levels, particularly NFL and pTau181, which suggests that plasma biomarkers are influenced primarily by age and genetic background rather than by metabolic factors in this cohort.

Carolin I. Kurz, Marleen Taute, Paulina Tegethoff et al. · 0 citations
Open access Aug 2026

Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis.

The findings indicate that a robust four-factor cognitive structure can be identified in clinically defined MCI cohorts without prior biological selection, and the association between latent memory factors and plasma p-tau217, observed primarily in cohorts with higher biomarker burden or clearer amnestic profiles, high...

Ana S. Perez, Hugo L. Hammer, V. Andersson et al. · 0 citations
Open access Aug 2026

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury.

W. Pelkmans, R. Cacciaglia, Michalis Kassinopoulos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.